Overview

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Status:
Terminated

Trial end date:
2013-06-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of retigabine/ezogabine as an adjunctive treatment in subjects with either partial onset seizures (12 to < 18 years old) or Lennox-Gastaut Syndrome (12 to <30 years old) who have participated in a previous ("parent") study.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborators:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Treatments:

Ezogabine